(RTTNews.com) - Seattle Genetics Inc. (SGEN) has initiated a phase Ib clinical trial evaluating SGN-75 in combination with everolimus for patients with advanced metastatic renal cell carcinoma or RCC. The study is designed to assess the safety and antitumor activity of SGN-75 in combination with everolimus. Seattle Genetics is a leader in the field of antibody-drug conjugates or ADCs and SGN-75 is an ADC targeted to CD70.

The study is a phase Ib, open-label, dose-escalation trial to evaluate the safety and antitumor activity of SGN-75 in combination with everolimus, an mTOR inhibitor, in patients with CD70-positive metastatic RCC. Everolimus is an oral prescription medication used to treat advanced RCC when certain other medicines, such as sunitinib or sorafenib,have not worked.

The trial is enrolling patients who have earlier been treated with one or two tyrosine kinase inhibitors or TKIs. The primary endpoint is safety, with key secondary endpoints of best clinical response, progression-free survival (PFS) and overall survival (OS). The study is expected to enroll up to 40 patients at multiple centers in the U.S.

For comments and feedback: contact editorial@rttnews.com

http://www.rttnews.com

Go here to see the original:
Seattle Genetics Begins Phase Ib Study Of SGN-75 Combined With Everolimus

Comments are closed.